保留比值受损肺功能与心血管结局的关系:一项大型前瞻性队列研究
在UK Biobank队列中,纳入基线(2006-2010)无心血管病且有肺功能检查的329,954名参与者,分析基线PRISm与MACE、心梗、卒中、心衰及心血管死亡的关系;其中22,781人在平均8.9年后复查肺功能,用于轨迹分析。多因素调整后,基线PRISm(vs 正常肺功能)与MACE(HR 1.26,95%CI 1.17-1.35)、心衰(HR 1.88,95%CI 1.72-2.05)、卒中(HR 1.26,95%CI 1.13-1.40)、心血管死亡(HR 1.55,95%CI 1.37-1.76)风险升高相关。轨迹分析显示,持续性PRISm(HR 1.96,95%CI 1.24-3.09)及气流阻塞(HR 1.43,95%CI 1.00-2.04)与MACE发生率升高相关;与持续性PRISm相比,PRISm转为正常肺功能与MACE发生率降低相关(HR 0.42,95%CI 0.19-0.99)。
要点
- 基线PRISm(vs 正常肺功能)与心衰风险升高相关最明显:HR 1.88(95%CI 1.72-2.05)。
- 基线PRISm还与MACE(HR 1.26,95%CI 1.17-1.35)、卒中(HR 1.26,95%CI 1.13-1.40)、心血管死亡(HR 1.55,95%CI 1.37-1.76)风险升高相关。
- 持续性PRISm与MACE发生率升高相关(HR 1.96,95%CI 1.24-3.09),气流阻塞亦相关(HR 1.43,95%CI 1.00-2.04)。
- 与持续性PRISm相比,PRISm转为正常肺功能与MACE发生率降低相关(HR 0.42,95%CI 0.19-0.99)。
- 基线PRISm与心梗风险升高相关:HR 1.12(95%CI 1.01-1.25)。
适用人群与场景
- UK Biobank队列中基线(2006-2010)无心血管病且具有肺功能检查(FEV1和FVC值)的参与者,用于基线分析(329,954人)。
- 具有基线及随访肺功能(2014-2020)的参与者纳入肺功能轨迹分析(22,781人,平均随访8.9年)。
研究设计与关键结果
- 研究类型为UK Biobank前瞻性队列研究,基线分析纳入329,954名无心血管病且基线有肺功能检查的参与者,轨迹分析纳入22,781名有随访肺功能者(平均8.9年)。
- 基线PRISm(vs 正常肺功能)多因素调整后HR:MACE 1.26(95%CI 1.17-1.35)、心梗 1.12(95%CI 1.01-1.25)、心衰 1.88(95%CI 1.72-2.05)、卒中 1.26(95%CI 1.13-1.40)、心血管死亡 1.55(95%CI 1.37-1.76)。
- 轨迹分析:与持续正常肺功能相比,持续性PRISm与MACE发生率升高相关(HR 1.96,95%CI 1.24-3.09),气流阻塞亦相关(HR 1.43,95%CI 1.00-2.04)。
- 与持续性PRISm相比,从PRISm转为正常肺功能与MACE发生率降低相关(HR 0.42,95%CI 0.19-0.99)。
证据类型、等级与局限
- 证据类型:大型前瞻性队列研究(UK Biobank)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基线或持续性PRISm者即使调整多种混杂因素后仍有多重心血管结局风险升高;从PRISm转为正常肺功能者心血管风险与正常肺功能者相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Preserved ratio impaired spirometry (PRISm) findings are a heterogeneous condition characterized by a normal FEV1 to FVC ratio with underlying impairment of pulmonary function. Data relating to the association of baseline and trajectories of PRISm findings with diverse cardiovascular outcomes are sparse.
RESEARCH QUESTION: How do baseline and trajectories of PRISm findings impact subsequent cardiovascular events?
STUDY DESIGN AND METHODS: In the UK Biobank cohort study, we included participants free of cardiovascular disease (CVD) with spirometry (FEV1 and FVC values) at baseline (2006-2010). Participants with baseline spirometry and follow-up spirometry (2014-2020) were included in the lung function trajectory analysis. Cox proportional hazards multivariate regression was performed to evaluate the outcomes of major adverse cardiovascular events (MACEs), incident myocardial infarction (MI), stroke, heart failure (HF), and CVD mortality in association with lung function.
RESULTS: For baseline analysis (329,954 participants), the multivariate adjusted hazard ratios (HRs) for participants had PRISm findings (vs normal spirometry findings) were 1.26 (95% CI, 1.17-1.35) for MACE, 1.12 (95% CI, 1.01-1.25) for MI, 1.88 (95% CI, 1.72-2.05) for HF, 1.26 (95% CI, 1.13-1.40) for stroke, and 1.55 (95% CI, 1.37-1.76) for CVD mortality, respectively. A total of 22,781 participants underwent follow-up spirometry after an average of 8.9 years. Trajectory analysis showed that persistent PRISm findings (HR, 1.96; 95% CI, 1.24-3.09) and airflow obstruction (HR, 1.43; 95% CI, 1.00-2.04) was associated with a higher incidence of MACE vs consistently normal lung function. Compared with persistent PRISm findings, changing from PRISm to normal spirometry findings was associated with a lower incidence of MACE (HR, 0.42; 95% CI, 0.19-0.99).
INTERPRETATION: Individuals with baseline or persistent PRISm findings were at a higher risk of diverse cardiovascular outcomes even after adjusting for a wide range of confounding factors. However, individuals who transitioned from PRISm to normal findings showed a similar cardiovascular risk as those with normal lung function.
参考来源
- Zheng J, Zhou R, Zhang Y, et al. Preserved Ratio Impaired Spirometry in Relationship to Cardiovascular Outcomes: A Large Prospective Cohort Study. Chest. 2022. PMID: 36372304. doi:10.1016/j.chest.2022.11.003
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。